Abstract
Aim:
To develop a homogeneous binding assay for high-throughput screening (HTS) of hit compounds at human neuromedin U receptor (hNMU-R) 1 and to identify non-peptidic small molecule hNMU-R modulators through functional assessments and structure-activity relationship (SAR) analyses.
Methods:
Membrane preparations of Chinese hamster ovary cells (CHO-K1) stably expressing hNMU-R1, [125I]hNMU-25, and wheat germ agglutinin-coupled microbeads were used to develop an HTS assay based on scintillation proximity assay (SPA) technology. This method was applied to a large-scale screening campaign against a diverse library of 36 000 synthetic compounds or natural products and subsequent confirmation studies. CHO-K1 cells stably expressing full-length hNMU-R1 or hNMU-R2 and a calcium-sensitive dye were employed to functionally measure intracellular calcium mobilization upon ligand stimulation. Preliminary SAR was determined based on limited structural modifications.
Results:
The Ki value (0.7 nmol/L) of hNMU-25 (the natural ligand) at hNMU-R1 measured by the SPA method was consistent with that reported in the literature, and the Z' factor for this HTS assay was 0.81. A total of 100 hits, showing more than 30% competitive inhibition on [125I]hNMU-25 binding to hNMU-R1, were identified initially, 3 of which were confirmed thereafter to have reasonable hNMU-R1-binding affinities and similar chemical structures. Based on their common molecular skeleton, 203 analogs were synthesized and tested. Among the 16 analogs that retained variable hNMU-R1-binding abilities, 2 elicited calcium influx in both hNMU-R1 and hNMU-R2-expressing cells, but none displayed antagonist activity.
Conclusion:
The homogeneous hNMU-R1 binding assay is an efficient and robust tool for screening potential hNMU-R modulators. Two non-selective hNMU-R agonists discovered are of low molecular weight nature with novel chemical structures. The preliminary SAR investigation suggests that both the triphenyl and guanidinol groups are crucial to the bioactivities observed.
Similar content being viewed by others
Article PDF
References
Minamino N, Sudoh T, Kangawa K, Matsuo H . Neuromedins: novel smooth-muscle stimulating peptides identified in porcine spinal cord. Peptides 1985; 6 Suppl 3: 245–8.
Minamino N, Kangawa K, Matsuo H . Neuromedin U-8 and neuromedin U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal-cord. Biochem Biophys Res Commun 1985; 130: 1078–85.
Brighton PJ, Szekeres PG, Willars GB . Neuromedin U and its receptors: structure, function and physiological roles. Pharmacol Rev 2004; 56: 231–48.
Sumi S, Inoue K, Kogire M, Doi R, Takaori K, Tobe T, et al. Effect of synthetic neuromedin U-8 and U-25, novel peptides identified in porcine spinal-cord, on splanchnic circulation in dogs. Life Sci 1987; 41: 1585–90.
Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Liu Q, et al. Identification of receptors for neuromedin U and its role in feeding. Nature 2000; 406: 70–4.
Nakazato M, Hanada R, Murakami N, Date Y, Mondal MS, Matsukura S, et al. Central effects of neuromedin U in the regulation of energy homeostasis. Biochem Biophys Res Commun 2000; 277: 191–4.
Ivanov TR, Lawrence CB, Stanley PJ, Luckman SM . Evaluation of neuromedin U actions in energy homeostasis and pituitary function. Endocrinology 2002; 143: 3813–21.
Hanada R, Nakazato M, Murakami N, Sakihara S, Yoshimatsu H, Sakata T, et al. A role for neuromedin U in stress response. Biochem Biophys Res Commun 2001; 289: 225–8.
Yu XH, Cao CQ, Mennicken F, Puma C, Dray A, Perkins M, et al. Pro-nociceptive effects of neuromedin U in rat. Neuroscience 2003; 120: 467–74.
Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Wong DT, et al. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 2001; 20: 6196–204.
Shetzline SE, Rallapalli R, Dowd KJ, Zou SM, Nakata Y, Gewirtz AM, et al. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood 2004; 104: 1833–40.
Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M, Theodorescu D . Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2006; 26: 765–73.
Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kojima M, et al. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 2005; 202: 217–24.
Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Habata Y, Hinuma S, et al. Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3. J Biol Chem 2000; 275: 21068–74.
Hosoya M, Moriya T, Kawamata Y, Ohkubo S, Fujii R, Matsui H, et al. Identification and functional characterization of a novel subtype of neuromedin U receptor. J Biol Chem 2000; 275: 29528–32.
Kojima M, Haruno R, Nakazato M, Date Y, Murakami N, Hanada R, et al. Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). Biochem Biophys Res Commun 2000; 276: 435–8.
Shan L, Qiao X, Crona JH, Behan J, Wang S, Laz T, et al. Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J Biol Chem 2000; 275: 39482–6.
Szekeres PG, Muir AI, Spinage LD, Miller JE, Butler SI, Smith A, et al. Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3. J Biol Chem 2000; 275: 20247–50.
Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Adham N et al. Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. J Biol Chem 2000; 275: 32452–9.
Qian J, Voorbach MJ, Huth JR, Coen ML, Zhang HC, Ng SC, et al. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal Biochem 2004; 328: 131–8.
Cheng Y, Prusoff WH . Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099–108.
Zhang JH, Chung TD, Oldenburg KR . A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67–73.
Hashimoto T, Masui H, Uchida Y, Sakura N, Okimura K . Agonistic and antagonistic activities of neuromedin U-8 analogs substituted with glycine or D-amino acid on contractile activity of chicken crop smooth muscle preparations. Chem Pharm Bull (Tokyo) 1991; 39: 2319–22.
Sakura N, Ohta S, Uchida Y, Kurosawa K, Okimura K, Hashimoto T . Structure-activity relationships of rat neuromedin U for smooth muscle contraction. Chem Pharm Bull (Tokyo) 1991; 39: 2016–20.
Sakura N, Kurosawa K, Hashimoto T . Structure-activity relationships of neuromedin U. I. Contractile activity of dog neuromedin U-related peptides on isolated chicken crop smooth muscle. Chem Pharm Bull (Tokyo) 1995; 43: 1148–53.
Hashimoto T, Kurosawa K, Sakura N . Structure-activity relationships of neuromedin U. II. Highly potent analogs substituted or modified at the N-terminus of neuromedin U-8. Chem Pharm Bull (Tokyo) 1995; 43: 1154–7.
Kurosawa K, Sakura N, Hashimoto T . Structure-activity relationships of neuromedin U. III. Contribution of two phenylalanine residues in dog neuromedin U-8 to the contractile activity. Chem Pharm Bull (Tokyo) 1995; 44: 1180–4.
Sakura N, Kurosawa K, Hashimoto T . Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity. Chem Pharm Bull (Tokyo) 2000; 48: 1166–70.
Abiko T, Takamura Y . Synthesis of two neuromedin U (NMU) analogues and their comparative effect of reducing food intake in rats. Prep Biochem Biotechnol 2002; 32: 79–86.
Wu B, Gao J, Wang MW . Development of a complex scintillation proximity assay for high-throughput screening of PPARy modulators. Acta Pharmacol Sin 2005; 26: 339–44.
Hui X, Gao J, Xie X, Suto N, Ogiku T, Wang MW . A robust homogeneous binding assay for α4β2 nicotinic acetylcholine receptor. Acta Pharmacol Sin 2005; 26: 1175–80.
Go bel J, Saussy DL, Goetz AS . Development of scintillation-proximity assays for alpha adrenoceptors. J Pharmacol Toxicol Methods 1999; 42: 237–44.
Gleich A, Schmidtchen FP, Mikulcik P, Müller G . Enantiodifferentiation of carboxylates by chiral building blocks for abiotic anion receptors. J Chem Soc Chem Commun 1990; 55–7.
Foye WO, Lemke TL, Williams DA (eds). Foye's principles of medicinal chemistry; v 4. Pennsylvania: Williams and Wilkins; 1995. Chapters 11–14, 17–18.
Kajino M, Hinuma S, Tarui N, Yamashita T, Nakayama Y, inventors; Receptor regulator. EP 1 559 428 A1, 03.08.2005.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Project supported in part by grants from the National Natural Science Foundation of China (No 30230400), the Ministry of Science and Technology of China (No 2004CB518902), Shanghai Municipality Government (No 30219228, 06DZ22907, and 07DZ22920), and Actelion Pharmaceuticals, Switzerland.
Rights and permissions
About this article
Cite this article
Meng, T., Su, Hr., Binkert, C. et al. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay. Acta Pharmacol Sin 29, 517–527 (2008). https://doi.org/10.1111/j.1745-7254.2008.00769.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00769.x
Keywords
This article is cited by
-
Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay
Acta Pharmacologica Sinica (2013)